Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

9431 ARTÍCULOS , VIENDO DEL 9301 AL 9315

Huntington's disease phenocopy syndromes revisited: a clinical comparison and next-generation sequencing exploration

Koriath CAM, Guntoro F, Norsworthy P, Dolzhenko E, Eberle M, Hensman Moss DJ, Flower M, Hummerich H, Rosser AE, Tabrizi SJ, Mead S, Wild EJ.

J Neurol Neurosurg Psychiatry. 2025 Apr 10;96(5):466-469. doi: 10.1136/jnnp-2024-333602.

Differentiating Hyperkinetic and Hypokinetic Motor Features in the Progression of Huntington's Disease

Halabi N, Killoran A, Nopoulos PC, Schultz JL.

medRxiv [Preprint]. 2025 Apr 21:2025.04.17.25325819. doi: 10.1101/2025.04.17.25325819.

Movement disorders: a brief overview from an evolutionary perspective

Garcia Ruiz PJ.

J Neural Transm (Vienna). 2025 Nov;132(11):1629-1633. doi: 10.1007/s00702-025-03025-8. Epub 2025 Oct 15.

Efficacy and safety of cholinesterase inhibitors and memantine for cognitive symptoms in patients with Huntington's disease: A systematic review

Rodrigues CC, Carvalho V, Sotero FD, Mulroy E, Guedes LC.

J Huntingtons Dis. 2025 Nov;14(4):331-339. doi: 10.1177/18796397251367689. Epub 2025 Aug 12.

The role of dopaminergic signalling from physiology to neuroprotection in acute and chronic disorders

Di Nunzio M, Mignogna ML, Bacigaluppi M, Panina-Bordignon P, Ragonese P, Muzio L, Summa V, Martino G.

Neurobiol Dis. 2025 Dec;217:107194. doi: 10.1016/j.nbd.2025.107194. Epub 2025 Nov 15.

Basal ganglia contributions to social cognition: evidence from movement disorders

Eddy CM.

Cogn Neuropsychiatry. 2025 Jan;30(1):1-14. doi: 10.1080/13546805.2025.2490054. Epub 2025 Apr 11.

Exploring Novel Therapeutic Avenues: Drug Repurposing for Neurodegenerative Movement Disorders

Bassi P, Rana S, Sapra V, Raina A, Kumar P, Devi S.

Curr Drug Res Rev. 2025;17(3):375-393. doi: 10.2174/0125899775327220240822111611.

Huntington's disease-like 2 patients' profile in a Brazilian cohort

Boone DL, Tumas V, Vilela G, Borges V, Rodrigues Pinto RAS, Costa MC, Ferraz HB.

Parkinsonism Relat Disord. 2025 Oct;139:108023. doi: 10.1016/j.parkreldis.2025.108023. Epub 2025 Sep 3.

Update on the Symptomatic Treatment of Huntington's Disease: From Pathophysiology to Clinical Practice

Olmedo-Saura G, Bernardi E, Bojtos L, Martínez-Horta S, Pagonabarraga J, Kulisevsky J, Pérez-Pérez J.

Int J Mol Sci. 2025 Jun 27;26(13):6220. doi: 10.3390/ijms26136220.

Challenges in studying disparities in neuropsychiatric hyperkinetic movement disorders

Dy-Hollins ME, Mendizabal A, Tsai AC.

Curr Opin Neurol. 2025 Aug 1;38(4):343-348. doi: 10.1097/WCO.0000000000001379. Epub 2025 May 16.

The microbiota-gut-brain axis in Huntington's disease: pathogenic mechanisms and therapeutic targets

Ekwudo MN, Gubert C, Hannan AJ.

FEBS J. 2025 Mar;292(6):1282-1315. doi: 10.1111/febs.17102. Epub 2024 Mar 1.

Systematic Review with Meta-Analysis of Biofluid Markers for Huntington's Disease

Paulsen JS, Bovin NA, Clemsen JD, Weiss A, Key AM, Janz ML, Pinto A, Burks DK, Zetterberg H, Shannon KM.

Mov Disord. 2025 Dec;40(12):2578-2595. doi: 10.1002/mds.70067. Epub 2025 Oct 13.

Genetic therapies for movement disorders - current status

Sartorelli J, Ng J, Rahim AA, Waddington SN, Kurian MA.

J Neurol. 2025 Feb 22;272(3):220. doi: 10.1007/s00415-025-12940-5.

Computer Vision Technologies in Movement Disorders: A Systematic Review

Pecoraro PM, Marsili L, Espay AJ, Bologna M, di Biase L.

Mov Disord Clin Pract. 2025 Sep;12(9):1229-1243. doi: 10.1002/mdc3.70123. Epub 2025 May 6.

Exploring the Role of Deutetrabenazine in the Treatment of Chorea Linked with Huntington's Disease

Tripathi S, Sharma Y, Kumar D.

Curr Rev Clin Exp Pharmacol. 2025;20(4):269-288. doi: 10.2174/0127724328312991241001051813.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias